Dolo 650 maker says drug part of Covid treatment, denies 'freebie' charges

In paracetamol market, Dolo's share rose to 24% from 15% pre-Covid-19

Bengaluru-based Micro Labs — the makers of popular paracetamol brand Dolo — said the use of 650 mg paracetamol as first line of Covid-19 treatment was a part of the national treatment guidelines issued by the Centre and thus became the drug of choice among doctors.

Micro Labs further said there was no specific reason to promote the 650 mg variant over the 500 mg as both are covered under price control. Speaking to Business Standard, Micro Labs executive VP Jayaraj Govindaraju strongly refuted charges of spending Rs 1,000 crore on handing out freebies to doctors to promote its paracetamol